PRKCI and ovarian cancer: With this AsiC (EpCAM-siPKCι aptamer), we achieved efficient knockdown of PKCι in ovarian cancer cells and detected dose-dependent apoptosis only in PRKCI-amplified ovarian cancer cells (Fig. 5).